- Regulatory Status
- RUO
- Other Names
- Neutrophil activating protein 2 (NAP2)
- Ave. Rating
- Submit a Review
- Product Citations
- publications
Cat # | Size | Price | Quantity Check Availability | Save | ||
---|---|---|---|---|---|---|
586702 | 10 µg | £137 | ||||
586704 | 25 µg | £238 |
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
CXCL7 is an ERL+ chemokine that is secreted by activated platelets, neutrophils, lymphocytes, and macrophages as a precursor. Pro-platelet basic protein or leukocyte derived grow factor (PPBP/LDGF) (a protein of ~14 kD) is modified by post-transcriptional cleavage to give rise to connective tissue activating peptide (CTAP-III), CXCL7, β-thromboglobulin (β-TG), and two variants of thrombocidin (TC-1 and TC-2). CTAP-III is activated by enzymatic proteolysis performed by cell surface-bound cathepsin G (CathG), a chymotryptic serine protease found in primary neutrophil granules. In this way, neutrophils are the mayor cells that convert CTAP-III into CXCL7. In addition, monocytes and mast cells can proteolytically modify CTAP-III to produce CXCL7. In fact, CathG has been detected in mast cells in addition to chymase, another chymotryptic enzyme. Further C-terminal truncations, that eliminate the last four and seven amino acids in CXCL7, generate two additional natural isoforms; these variants are more potent neutrophils activators.
High levels of CTAP-III have been detected in plasma of patients with lung cancer. In fact, it has been suggested as a biomarker for early lung cancer detection. An increase in positive immunostained cells has been detected in the bronchial submucosa of patients with stable severe chronic obstructive pulmonary disease. Also, studies with premalignant breast cancer cells transfected with CXCL7 showed that these cells became as invasive as malignant breast cancer cells. In addition, CXCL7 induces stimulation of the lymphangiogenic factors VEGF-C and VEGF-D in human breast cancer cells, suggesting an important role for CXCL7 in tumor invasion.
Product Details
- Source
- Mouse CXCL7, amino acids Ile48-Ile109 (Accession# NM_019932.4) was expressed in E. coli.
- Molecular Mass
- The 62 amino acid recombinant protein has a predicted molecular mass of approximately 6.7 kD. The DTT-reduced and non-reduced protein migrate at approximately 11 and 9 kD by SDS-PAGE respectively. The N-terminal amino acid is Ile.
- Purity
- >98%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in PBS.
- Endotoxin Level
- Less than 0.01 ng per µg cytokine as determined by the LAL method.
- Concentration
- 10 and 25 µg sizes are bottled at 200 µg/mL.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Recombinant mouse CXCL7 (NAP-2) chemoattracts Baf3-mCXCR2 transfectants in a dose-dependent manner. The ED50 for this effect is 0.4– 3.0 ng/mL.
- Application
-
BA - Quality tested
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Distribution
-
Platelets, neutrophils, lymphocytes, macrophages, endothelial cells
- Function
- CXCL7 stimulates chemotaxis and degranulation in neutrophils, induces transendothelial migration and neutrophil adhesion to activated endothelial cells, and has angiogenic activity. LPS induces the precursor in PBMCs.
- Interaction
- Neutrophils, keratinocytes
- Ligand/Receptor
- CXCR2
- Biology Area
- Cell Biology, Signal Transduction
- Molecular Family
- Cytokines/Chemokines
- Antigen References
-
1. Iida N, et al. 1996 FASEB J. 10:1336.
2. Schenk BI, et al. 2002 J. Immunol. 169:2602.
3. El-Gedaily A, et al. 2004. J. Leukoc. Biol. 75:495.
4. Schiemann F, et al. 2006. Blood 107:2234.
5. Tang Z, et al. 2008. Am. J. Surg. 196:690.
6. Yee J, et al. 2009. J. Clin. Oncol. 27:2787.
7. Yu M, et al. 2010. J. Oncol. 2010:939407.
8. Lee G, et al. 2011. Am. J. Transl. Res. 3:226.
9. Nguyen LT and Vogel HJ. 2012. Front. Immunol. 3:1. - Gene ID
- 57349 View all products for this Gene ID
- UniProt
- View information about CXCL7 on UniProt.org
Related FAQs
- Why choose BioLegend recombinant proteins?
-
• Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
• Greater than 95% Purity or higher, tested on every lot of product.
• 100% Satisfaction Guarantee for quality performance, stability, and consistency.
• Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
• Bulk and customization available. Contact us.
• Learn more about our Recombinant Proteins. - How does the activity of your recombinant proteins compare to competitors?
-
We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
- What is the specific activity or ED50 of my recombinant protein?
-
The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
- Have your recombinants been tested for stability?
-
Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
- Does specific activity of a recombinant protein vary between lots?
-
Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
- How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
-
Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)
Follow Us